Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/EBIT ratio high or low?
The EV/EBIT ratio of 16.81x is in line with its 5-year average of 16.10x, around the middle of its 5-year range (14.30x–20.03x).
2.03% above its 12-month average of 16.48x.
Reported annual fiscal-period values; no daily interpolation.
EV/EBIT RATIO
16.81x
EV/EBIT RATIO AVG TTM
16.48x
EV/EBIT RATIO AVG 3Y
15.43x
EV/EBIT RATIO AVG 5Y
16.10x
EV/EBIT RATIO AVG 10Y
14.89x
EV/EBIT RATIO AVG 15Y
13.75x
EV/EBIT RATIO AVG 20Y
14.27x
CURRENT VS TTM AVG
+2.03%
CURRENT VS 3Y AVG
+8.93%
CURRENT VS 5Y AVG
+4.41%
CURRENT VS 10Y AVG
+12.87%
CURRENT VS 15Y AVG
+22.21%
CURRENT VS 20Y AVG
+17.78%
SECTOR MEDIAN · HEALTHCARE
22.40x
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-24.96%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
EV/EBIT Ratio
16.81x
TTM Avg
16.48x
3Y Avg
15.43x
5Y Avg
16.10x
Market Cap
$358.76B
EV/EBIT Ratio
18.58x
TTM Avg
16.37x
3Y Avg
15.82x
5Y Avg
17.30x
Market Cap
$369.34B
EV/EBIT Ratio
38.49x
TTM Avg
14.92x
3Y Avg
30.97x
5Y Avg
27.22x
Market Cap
$255.15B
EV/EBIT Ratio
20.52x
TTM Avg
23.35x
3Y Avg
25.90x
5Y Avg
345.73x
Market Cap
$234.38B
EV/EBIT Ratio
33.25x
TTM Avg
29.26x
3Y Avg
30.37x
5Y Avg
28.69x
Market Cap
$205.42B
EV/EBIT Ratio
10.17x
TTM Avg
11.02x
3Y Avg
22.89x
5Y Avg
24.90x
Market Cap
$193.04B
EV/EBIT Ratio
28.54x
TTM Avg
26.48x
3Y Avg
30.01x
5Y Avg
27.58x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 16.81x | 16.48x | 15.43x | 16.10x |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 18.58x | 16.37x | 15.82x | 17.30x |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 38.49x | 14.92x | 30.97x | 27.22x |
| AbbVie Inc. (ABBV)vs › | $455.87B | 28.07x | 37.03x | 32.50x | 26.83x |
| AstraZeneca PLC (AZN)vs › | $255.15B | 20.52x | 23.35x | 25.90x | 345.73x |
| Amgen Inc. (AMGN)vs › | $235.85B | 22.36x | 23.50x | 26.49x | 23.42x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 33.25x | 29.26x | 30.37x | 28.69x |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 10.17x | 11.02x | 22.89x | 24.90x |
| Abbott Laboratories (ABT)vs › | $193.04B | 28.54x | 26.48x | 30.01x | 27.58x |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 15.80x | 17.78x | 42.82x | 31.25x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2025-12-31 | 15.71x |
| 2024-12-31 | 17.24x |
| 2023-12-31 | 14.30x |
| 2022-12-31 | 14.48x |
| 2021-12-31 | 20.03x |
| 2020-12-31 | 14.84x |
| 2019-12-31 | 13.26x |
| 2018-12-31 | 11.68x |
| 2017-12-31 | 13.02x |
| 2016-12-31 | 12.82x |
| 2015-12-31 | 16.44x |
| 2014-12-31 | 15.23x |
| 2013-12-31 | 13.88x |
| 2012-12-31 | 10.86x |
| 2011-12-31 | 11.79x |
| 2010-12-31 | 10.77x |
| 2009-12-31 | 15.48x |
| 2008-12-31 | 10.07x |
| 2007-12-31 | 11.71x |
| 2006-12-31 | 16.24x |
| 2005-12-31 | 19.87x |
| 2004-12-31 | 13.13x |
| 2003-12-31 | 20.55x |
| 2002-12-31 | 50.57x |
| 2001-12-31 | 24.19x |
| 2000-12-31 | 14.10x |
| 1999-12-31 | 16.36x |
| 1998-12-31 | 33.27x |
